Navigation Links
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Date:6/1/2014

CHICAGO Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting.

The addition of bevacizumab to standard therapy extended progression-free survival more for ovarian cancer patients with molecular subtypes labeled as "proliferative" or "mesenchymal" compared to those with subtypes labeled as "immunoreactive" or "differentiated," says Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist and senior author of the study. "Though our study is very preliminary, it does suggest that we are getting close to the point where we could use sequencing data to choose more effective and less toxic therapies for patients."

Dr. Dowdy says the U.S. spends about $3 billion a year on bevacizumab for cancer treatment. "Unfortunately, two-thirds of those patients don't respond to the drug, which means we are just giving them toxicity with no benefit. This expression data will help us choose which patients should receive this drug."

Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels that help cancers grow and spread. An international phase 3 clinical trial known as ICON7 has recently shown that adding this drug to the first-line chemotherapy drugs carboplatin and paclitaxel can improve progression-free survival of ovarian cancer patients.

Dr. Dowdy and his colleagues wanted to determine if the response to this new treatment could be predicted by looking at the molecular makeup of ovarian tumors. First, the researchers used gene expression arrays to analyze biopsies preserved in paraffin-embedded tissue blocks from ICON7 patients.

Then, they used the molecular classification already established by the National Cancer Institute's Cancer Genome Atlas (TCGA) project to separate the
'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Mayo Clinic: Drug induces morphologic, molecular and clinical remissions in myelofibrosis
2. Mayo Clinic: Add bone deterioration to diabetes complications
3. Mayo Clinic: Researchers to study bodys defense system to find new treatments for Alzheimers
4. Mayo Clinic: Less-invasive option as effective as esophagus removal in early esophageal cancer
5. Mayo Clinic: Enhanced recovery pathway for gynecologic surgery gets patients back to health faster
6. Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
7. Mayo Clinic: Rotavirus vaccine given to newborns in Africa is effective
8. Mayo Clinic: How gold nanoparticles can help fight ovarian cancer
9. Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
10. Mayo Clinic: Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma
11. Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... patients die annually as a result of preventable medical harm—this ... each day. Now more than ever before, hospitals and patients ... they can to stay safe. , Through an exclusive ... discusses the importance of safer hospitals. “It’s incumbent upon all ... ensure that all our patients are in the safest environment ...
(Date:2/27/2015)... 27, 2015 Muscular Dystrophy Association ... Engineering at Duke University, recently announced a potentially ... young men with Duchenne muscular dystrophy (DMD). The ... and Gersbach will discuss their implications at MDA's ... in Washington, D.C. , Background: Gersbach and ...
(Date:2/27/2015)... 2015 Over 440,000 patients die each year ... now to educate readers on how they can take control ... serve as a guide to educate and inspire readers to ... loved ones safe with tips on topics ranging from hospital ... cover of the print publication. He recently spoke to ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 With cases of ... Dade area, concerned parents look to school administrations to help ... screenings. Though head lice is a common parasite that passes ... a nuisance, causing parents and teachers significant distress. , ... screenings at the school. This would allow parents and ...
(Date:2/27/2015)... Schenectady, New York (PRWEB) February 27, 2015 ... has been named one of the Best Companies to ... , “Transfinder recognizes the importance of creating a great ... a demanding – yet professionally fulfilling – environment. There’s ... doing great work together,” said Antonio Civitella, president and ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2Health News:South Florida Parents Put Pressure on Schools to Perform Lice Screenings to Prevent Spread of Lice According to One Miami Lice Removal Company Called Lice Troopers 2Health News:Transfinder Named a Best Company to Work for in New York State 2
... PLC (OTC,Bulletin Board: SNKTY), a Life Sciences company ... science of healthy aging, today announced,that its North ... an,amount up to $28 million to further advance ... including Invicorp(R)., Plethora Solutions Holdings PLC, a ...
... the POA, indicator reporting requirements by implementing data elements that expand, ... healthcare ... claims., ... their commitment for continuous improvement is,evident by assisting clients with compliance ...
... for future of loved ones with special ... ... Mutual,Life Insurance Company (MassMutual) today made available on its Web site a,free ... begin,developing or supplementing life care plans for family members with a,disability or ...
... ... With U.S. Presence, AMSTERDAM, The Netherlands, ... evolving field of cancer molecular diagnostics,today announced the appointment of Richard ... medical officer (CMO). Dr. Bender, who,will report directly to Chief Executive ...
... The U.S. Agency,for International Development (USAID) highlights ... the Agency,s community partnerships,in Africa as part of ... this,week. Admiral Timothy Ziemer, U.S. Malaria Coordinator, and ... join Jay Hein,Director of the White House Office ...
... the California NanoSystems Institute at UCLA have developed a novel ... inside tiny pores and release them into cancer cells in ... "nanoimpeller," the device is the first light-powered nanomachine that operates ... for cancer treatment. , UCLA researchers reported ...
Cached Medicine News:Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4Health News:Data Dimensions Assists Clients With Compliance of 'Present on Admission' (POA) Indicator Reporting Requirements as Part of the April 1, 2008 Timeline 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 3Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 3Health News:USAID Participates in White House Office of Faith-Based and Community Initiatives Conferences in Rwanda and Zambia 2Health News:UCLA researchers design nanomachine that kills cancer cells 2Health News:UCLA researchers design nanomachine that kills cancer cells 3
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... Feb. 27, 2015  In recognition of Rare Disease ... the global bleeding disorders community, CSL Behring ... units (IUs) of protein therapies to the World Federation ... organization which has worked to improve the lives of ... donation supports the WFH,s Global Alliance for Progress (GAP) ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... McLaren Health Care and its Great,Lakes Cancer ... medical,minds to share the latest work underway around ... October 11th symposium, hosted by,McLaren and GLCI, was ... oncologist whose work in sentinel node mapping for,colorectal ...
... Changes Induced by ... in Patients with Celiac Disease, Additional Data Indicates Potential in ... Alba Therapeutics Corporation,presented results from two clinical studies this week ... Data from,study CLIN 1001-004, the first Phase IIa trial conducted ...
Cached Medicine Technology:News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6